Yaqiong Chen

Yaqiong (Joan) Chen, Ph.D., serves as Vice President at Decheng Capital since July 2025, having previously held the position of Senior Associate at 5Y Capital from January 2024 to July 2025, where key transactions included LTZ Therapeutics, Syneron Bio, and Allink Biotherapeutics. Prior experience includes Vice President at Delos Capital from August 2020 to September 2023, leading notable US and China transactions, and an Associate role at Charles River Associates as a Life Sciences Consultant, focusing on opportunity assessment and investment asset valuation. Yaqiong Chen's educational background includes a PhD, MPhil, and MA in Biological Sciences from Columbia University, a healthcare strategy cross-registration at Columbia Business School, and a BS (Magna cum laude) in Life Sciences from Tsinghua University.